.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022173

« Back to Dashboard
NDA 022173 describes ZYPREXA RELPREVV, which is a drug marketed by Eli Lilly Co and is included in one NDA. It is available from one supplier. There is one patent protecting this drug. Additional details are available on the ZYPREXA RELPREVV profile page.

The generic ingredient in ZYPREXA RELPREVV is olanzapine pamoate. There are thirty-three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the olanzapine pamoate profile page.

Summary for NDA: 022173

Tradename:
ZYPREXA RELPREVV
Applicant:
Eli Lilly Co
Ingredient:
olanzapine pamoate
Patents:1
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 022173

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173 NDA Eli Lilly and Company 0002-7635 0002-7635-11 1 KIT in 1 CARTON (0002-7635-11) * 1.4 mL in 1 VIAL (0002-7658-01) * 3 mL in 1 VIAL (0002-7622-01)
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022173 NDA Eli Lilly and Company 0002-7636 0002-7636-11 1 KIT in 1 CARTON (0002-7636-11) * 2 mL in 1 VIAL (0002-7659-01) * 3 mL in 1 VIAL (0002-7622-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, EXTENDED RELEASE;INTRAMUSCULARStrengthEQ 210MG BASE/VIAL
Approval Date:Dec 11, 2009TE:RLD:No
Patent:6,169,084Patent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, EXTENDED RELEASE;INTRAMUSCULARStrengthEQ 300MG BASE/VIAL
Approval Date:Dec 11, 2009TE:RLD:No
Patent:6,169,084Patent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:SUSPENSION, EXTENDED RELEASE;INTRAMUSCULARStrengthEQ 405MG BASE/VIAL
Approval Date:Dec 11, 2009TE:RLD:Yes
Patent:6,169,084Patent Expiration:Sep 30, 2018Product Flag?YSubstance Flag?YDelist Request?
Patented Use:A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS.

Expired Orange Book Patents for NDA: 022173

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-001Dec 11, 20095,229,382*PED► subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-003Dec 11, 20095,229,382*PED► subscribe
Eli Lilly Co
ZYPREXA RELPREVV
olanzapine pamoate
SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR022173-002Dec 11, 20095,229,382*PED► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc